ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1177

Talin Is Cleaved and Expressed As a Short Form in Patients with Rheumatoid Arthritis

Kensei Tsuzaka1, Masako Takao1, Naoshi Shinozaki2 and Jiro Nishida1, 1Dept of Internal Medicine, Ichikawa General Hospital,TDC, Ichikawa, Chiba, Japan, 2Cornea Center, Ichikawa General Hospital, TDC, Ichikawa, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers, diagnosis and rheumatoid arthritis, pathogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumamtoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Talin has been known as a cytoskeletal protein, which, by binding to integrin beta-subunit, enhances the inside-out signaling from intracellular to extracellular of integrins, cell adhesion, cell migration, and causes chronic inflammation and angiogenesis. Last ACR meeting, we reported plasma talin was expressed predominantly in rheumatoid arthritis (RA) patients and it could be a candidate marker for the diagnosis and monitoring RA treatment. In this paper, we investigated the intracellular talin expression in RA patients.

Methods: RA was diagnosed as the 2010 Rheumatoid Arthritis Classification Criteria. Peripheral blood mononuclear cells (PBMC) were obtained from 42 RA patients, 20 SLE patients, and 31 normal healthy controls (NC)). PBMC was lysed with the lysis buffer, incubated with calpain1, and electrophoresed on SDS-PAGE gels. Membranes were blotted with anti-talin antibody H-18 that recognizes the N-terminus of the calpain1 fragment of talin or TA205 that reacts with its C-terminus. Talin fusion protein with GST (glutathione-S-transferase) was expressed using pGEX vector fused with talin cDNA.

Results: Western Blot analysis showed that the N-terminal 32kDa and the C-terminal 15kDa of calpain1 fragment of talin (32kDa and 15kDa short-talin, respectively) was expressed predominantly in RA patients [85.7% (36/42), 83.3% (35/42)] compared with NC [0% (0/31), 0% (0/31)] and SLE patients [25.0% (5/20), 30.0% (6/20)] (Fig.1, Fig.2). PBMC obtained from a NC was incubated with each of 4 RA patient PBMCs, lysed with the lysis buffer, incubated with calpain1, and were electrophoresed on a SDS-PAGE gel. Membrane was blotted with H-18. As a result, the wild-type calpain1 fragment (47kDa) of talin was degraded into 32kDa short-talin after incubating with each RA patient PBMC. Moreover, GST-talin fusion protein was cleaved into the short-talin after incubating with RA patient PBMC lysate, but was not cleaved with NC PBMC lysate. Surprisingly, Western Blot analysis using H-18 also showed predominant expression of the 32kDa short-talin in RA patient plasma.

Conclusion: Our findings suggest that the intracellular talin in RA patients is cleaved into short-talin and expressed predominantly in RA patient PBMC and plasma (Fig.3). This short-talin might be related to the pathogenesis of RA.


Disclosure:

K. Tsuzaka,
None;

M. Takao,
None;

N. Shinozaki,
None;

J. Nishida,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/talin-is-cleaved-and-expressed-as-a-short-form-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology